{
    "clinical_study": {
        "@rank": "136059", 
        "acronym": "T-OPTIMUM", 
        "arm_group": [
            {
                "arm_group_label": "Tacrolimus with low-dose corticosteroid", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High-dose corticosteroid alone", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the therapeutic effect of tacrolimus in combination with low-dose corticosteroid\n      with high-dose corticosteroid alone in patients with minimal-change nephrotic syndrome."
        }, 
        "brief_title": "A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Minimal Change Nephrotic Syndrome (MCNS)", 
            "MCNS"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Nephrotic Syndrome", 
                "Nephrosis, Lipoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients who have been diagnosed with initial or relapsed primary minimal-change\n             nephrotic syndrome\n\n          -  patients whose urine protein-creatinine ratio (UPCR) is more than 3.0\n\n        Exclusion Criteria:\n\n          -  patients whose eGFR is less than 30 ml/min/1.73 m2\n\n          -  patients who were treated with immunosuppressants, such as tacrolimus, cyclosporine,\n             cyclophosphamide (Cytoxan), mizoribine (Bredinin), levamisole, azathioprine,\n             mycophenolate mofetil, or rituximab, within two weeks before the study\n\n          -  patients to whom more than 10 mg prednisolone or an equivalent dose of steroid was\n             administered daily within two weeks before the study\n\n          -  patients who are pregnant, breastfeeding, or planning to be pregnant or to breastfeed\n             within six months after the study completion, or who cannot or do not want to use any\n             contraceptive method\n\n          -  patients who are hypersensitive to the investigational drug or to macrolide, such as\n             azithromycin, clarithromycin, or roxithromycin\n\n          -  patients who were treated with a live vaccine within four weeks before the study\n\n          -  patients whose liver panel laboratory test result is three times the normal range, or\n             acute hepatitis patients whose serum bilirubin has been clinically significantly\n             higher than 3.6 mg/dL for more than 1 month\n\n          -  patients who have a significant general disease that makes it inappropriate for them\n             to participate in this study as adjudged by the investigator (e.g.,\n             cardiovascular-acute myocardial infarction, heart failure [classified as more than\n             New York Heart Association {NYHA} class III], hepatic/gastrointestinal/neurologic\n             disease, blood disorder, cancer, infection, renal disorder other than minimal-change\n             nephrotic syndrome, rheumatic arthritis with pneumonia interstitials)\n\n          -  patients who have genetic problems such as galactose intolerance, Lapp lactose\n             deficiency, or glucose-galactose malabsorption\n\n          -  patients to whom another investigational drug was administered within 30 days from\n             the enrollment in the study\n\n          -  patients who participated in the past phases of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "78 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763580", 
            "org_study_id": "PRGNS-11-02-KOR"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tacrolimus with low-dose corticosteroid", 
                "description": "Oral", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "FK506, Prograf Capsule"
            }, 
            {
                "arm_group_label": [
                    "Tacrolimus with low-dose corticosteroid", 
                    "High-dose corticosteroid alone"
                ], 
                "description": "Oral", 
                "intervention_name": "Prednisolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Nephrotic syndrome", 
            "Tacrolimus", 
            "Glomerulonephritis"
        ], 
        "lastchanged_date": "January 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.\u00ae) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS)", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The percentage of subjects who show a decreased UPCR (Urine Protein Creatinine Rate) of less than 0.2", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763580"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The period until the UPCR is decreased below 0.2", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks after treatment"
            }, 
            {
                "measure": "The percentage of subjects who show relapse after the remission", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "The period until the relapse happens from the complete remission", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, labo-tests, vital signs, ECGs and chest X-rays", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Korea, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}